BONEY PRIYA P JOSE,AKSHAYA VISWANATHAN,NEHA BRAHMA,VIMAL S,DR. KISHORE KUMAR
DOI: https://doi.org/Cancer immunotherapy is limited by the immunosuppressive tumor microenvironment (TME), largely shaped by tumor-associated macrophages (TAMs). mRNA-based vaccines offer a novel strategy to reprogram TAMs from a tumor-promoting M2 to a tumoricidal M1 phenotype. Delivered via targeted lipid nanoparticles, these vaccines enhance anti-tumor immunity and synergize with checkpoint inhibitors. This approach holds promise for converting “cold” tumors into “hot,” improving outcomes in resistant cancers.
